Skip to main content
OpenTrials
Completed

NCT Number: NCT01235507

A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)

This open-label, single arm study will assess the safety and efficacy of RoActem ra/Actemra (tocilizumab) in combination with methotrexate in patients with activ e moderate to severe rheumatoid arthritis who have an inadequate response to dis ease-modifying antirheumatic drugs (DMARDs). Patients will receive RoActemra/Act emra at a dose of 8 mg/kg (maximum 800 mg) intravenously every 4 weeks for a tot al of 6 infusions. Methotrexate will be continued at a stable dose. Anticipated time on study treatment is 24 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rheumatoid Arthritis Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Banja Luka, Bosnia and Herzegovina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients, >/= 18 years of age
  • Active moderate to severe rheumatoid arthritis (RA)
  • On methotrexate treatment (oral or parenteral) for at least 12 weeks, at stable dose of at least 15 mg/week for at least 6 weeks
  • Oral corticosteroids must have been at stable dose of </= 10 mg/day prednisone (or equivalent) for at least 25 out of 28 days prior to first dose of study drug
  • Body weight </= 150 kg

Exclusion criteria

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months of study entry
  • Rheumatic autoimmune disease other than RA
  • Functional class IV according to American College of Rheumatology (ACR) classification
  • Prior history of or current inflammatory joint disease other then RA
  • Treatment with traditional DMARDs other than methotrexate within 1 month (for leflunomide 3 months) prior to baseline
  • Treatment with any biologic drug that is used in the treatment or RA
  • Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline
  • Known active current or history of recurrent infection
  • History of or currently active primary or secondary immunodeficiency
  • Positive for HIV

Treatment and study plan

methotrexate

Drug

stable dose as prescribed

tocilizumab [RoActemra/Actemra]

Drug

8 m/kg (maximum 800 mg) intravenously every 4 weeks for a total of 6 infusions

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs)

    Time frame: Screening Visit, Baseline, Weeks 4, 8, 12, 16, 20 and 24

    AEs, SAEs and AESI were recorded from the Screening Visit until the final visit at Week 24.

Secondary outcomes

  1. Mean Disease Activity Score Based on 28 Joint Count (DAS28) by Visit

    Time frame: Baseline, Weeks 8, 16 and 24

    DAS28 was calculated using the 28 joints count, the C-reactive protein levels (CRP) and participant's global assessment (PtGA) of disease activity. The following formula was used to determine DAS28.

    DAS28 (equals) = 0.56 × (square root of) √(TJC28) + 0.28 × √(SJC28) + 0.36 × ln(CRP+1) + 0.014 × GH + 0.96 where, TJC28 = tender joint count on 28 joints, SJC28 = swollen joint count on 28 joints, ln = natural log, CRP = C-reactive protein (mg/L), and GH = general health, determined by participant's global assessment of disease activity (100- millimeter [mm] visual analog scale [ VAS]).

    The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.

  2. Percentage of Participants Achieving Low Disease Activity (LDA) and Clinical Remission (CR) as Assessed Using DAS28

    Time frame: Weeks 8, 16 and 24

    DAS28 was calculated using the 28 joints count, the CRP and PtGA of disease activity. The following formula was used to determine DAS28.

    DAS28 = 0.56 × √(TJC28) + 0.28 × √(SJC28) + 0.36 × ln(CRP+1) + 0.014 × GH + 0.96 where, TJC28 = tender joint count on 28 joints, SJC28 = swollen joint count on 28 joints, ln = natural log, CRP = C-reactive protein (mg/L), and GH = general health, determined by participant's global assessment of disease activity (100-mm VAS).

    The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. Participants were considered to have low disease activity when DAS28 was less than or equal to (≤) 3.2 and in clinical remission when DAS28 scores were less than (<) 2.6

  3. Swollen and Tender Joint Counts

    Time frame: Baseline, Weeks 8, 16 and 24

    66 and 68 joints were assessed by the physician for tenderness or swelling respectively. The joints were counted as tender/not tender (tender=1; not tender=0) and swollen/not swollen (swollen=1; not swollen=0) and scored. The scores ranged from 0 to 66 for TJC and 0 to 68 for SJC. A negative change from baseline represents an improvement.

  4. Physician's Global Assessment of Disease Activity

    Time frame: Baseline, Weeks 8, 16 and 24

    Physician's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100). The distance in mm from the left edge of the scale was measured. Higher scores indicated higher disease activity. A negative change from baseline represents an improvement.

  5. Participant's Global Assessment of Disease Activity

    Time frame: Baseline, Weeks 8, 16 and 24

    Participant's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100). The distance in mm from the left edge of the scale was measured. Higher scores indicated higher disease activity. A negative change from baseline represents an improvement.

  6. Participant's Global Assessment of Pain

    Time frame: Baseline, Weeks 8, 16 and 24

    Participant's global assessment of pain was performed using a 100 mm VAS ranging from no pain (0) at the left edge to unbearable pain (100) at the right edge. The distance in mm from the left edge of the scale was measured. A negative change from baseline represents an improvement.

  7. CRP Levels

    Time frame: Baseline, Weeks 8, 16 and 24

    CRP is a marker of acute phase inflammation and is measured in mg/L. A negative change from baseline represents an improvement.

  8. Erythrocyte Sedimentation Rate (ESR)

    Time frame: Baseline, Weeks 8, 16 and 24

    ESR is a marker of inflammation and is measured in millimeters per hour (mm/hour). A negative change from baseline represents an improvement.

Sponsors and collaborators

Lead sponsor

Hoffmann-La Roche

Industry

Registry information

Official study title

Actemra - Local Bosnian Open, Multicentric, Trial to Evaluate Safety, Tolerability and Efficacy of Tocilizumab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis After Inadequate Response to DMARDs

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Nov 5, 2010
Registry last updated
Nov 7, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.